180 related articles for article (PubMed ID: 22878514)
1. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies.
Hauser RA; Truong D; Hubble J; Coleman C; Beffy JL; Chang S; Picaut P
J Neural Transm (Vienna); 2013 Feb; 120(2):299-307. PubMed ID: 22878514
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
3. Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport
Simonetta-Moreau M; Picaut P; Volteau M; Poewe W
Eur J Neurol; 2019 Jun; 26(6):943-e65. PubMed ID: 30168896
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A therapy for cervical dystonia.
Rodrigues FB; Duarte GS; Marques RE; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003633. PubMed ID: 33180963
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A therapy for cervical dystonia.
Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
7. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type B for cervical dystonia.
Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.
Evidente VG; Fernandez HH; LeDoux MS; Brashear A; Grafe S; Hanschmann A; Comella CL
J Neural Transm (Vienna); 2013 Dec; 120(12):1699-707. PubMed ID: 23779062
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
11. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.
Poewe W; Deuschl G; Nebe A; Feifel E; Wissel J; Benecke R; Kessler KR; Ceballos-Baumann AO; Ohly A; Oertel W; Künig G
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):13-7. PubMed ID: 9436721
[TBL] [Abstract][Full Text] [Related]
12. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
Laubis-Herrmann U; Fries K; Topka H
Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Duarte GS; Castelão M; Rodrigues FB; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004314. PubMed ID: 27782297
[TBL] [Abstract][Full Text] [Related]
15. A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.
Lew MF; Brashear A; Dashtipour K; Isaacson S; Hauser RA; Maisonobe P; Snyder D; Ondo W
Int J Neurosci; 2018 Jul; 128(7):619-626. PubMed ID: 29343142
[TBL] [Abstract][Full Text] [Related]
16. Cumulative effects of long-term treatment with abobotulinumtoxinA in cervical dystonia: Findings from a prospective, observational study.
Colosimo C; Charles D; Misra VP; Maisonobe P; Om S;
J Neurol Sci; 2020 Sep; 416():117015. PubMed ID: 32682125
[TBL] [Abstract][Full Text] [Related]
17. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
[TBL] [Abstract][Full Text] [Related]
18. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.
Trosch RM; Espay AJ; Truong D; Gil R; Singer C; LeWitt PA; Lew MF; Tagliati M; Adler CH; Chen JJ; Marchese D; Comella CL
J Neurol Sci; 2017 May; 376():84-90. PubMed ID: 28431634
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type A versus anticholinergics for cervical dystonia.
Rodrigues FB; Duarte GS; Castelão M; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD004312. PubMed ID: 33852744
[TBL] [Abstract][Full Text] [Related]
20. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]